DRD4抗体—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 30 μg, Lane: Mouse skeletal muscle tissue, Primary antibody: P10801(DRD4 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P10801(DRD4 Antibody) at dilution 1/5. (Original magnification: ×200)    

  
  

The dopamine D4 receptor (DRD4) is a G protein-coupled receptor (GPCR) primarily expressed in the central nervous system, particularly in regions like the prefrontal cortex, hippocampus, and amygdala. It plays a key role in modulating dopamine-mediated neurotransmission, influencing cognitive functions, emotional regulation, and reward pathways. DRD4 is notable for its genetic polymorphism, especially a variable number of tandem repeats (VNTR) in exon III, which has been linked to neuropsychiatric conditions such as attention-deficit/hyperactivity disorder (ADHD), schizophrenia, and addiction.

DRD4-specific antibodies are essential tools for studying receptor localization, expression levels, and signaling mechanisms in both research and clinical contexts. These antibodies enable techniques like immunohistochemistry, Western blotting, and flow cytometry to visualize DRD4 distribution in tissues or assess its protein dynamics under physiological or pathological conditions. They are also critical for investigating DRD4's interactions with ligands, antipsychotic drugs, or intracellular proteins. However, challenges persist in ensuring antibody specificity due to structural similarities among dopamine receptor subtypes. Validation via knockout controls or epitope mapping is often required. Advances in antibody engineering, such as monoclonal or recombinant formats, continue to improve precision, aiding research into DRD4's role in behavior, neurodevelopment, and therapeutic targeting for mental health disorders.